Trafalgar International (GCAN) Change in Account Payables (2019 - 2026)
Greater Cannabis Company (GCAN) posted quarterly Change in Account Payables of -$1000.0 for Q1 2026, down 706.06% year-over-year from $165.0 in Q1 2025, and down 198.51% quarter-over-quarter from -$335.0 in Q4 2025.
Trafalgar International (GCAN) Change in Account Payables (2019 - 2026) Analysis & Trends
Greater Cannabis Company's Change in Account Payables history runs 8 years deep, the most recent figure standing at -$1000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables fell 706.06% year-over-year to -$1000.0; the TTM figure through Mar 2026 stood at -$530.0 (down 129.69% YoY), while the FY2025 annual figure was $635.0, down 64.43% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$1000.0, down from -$335.0 in the prior quarter.
- The five-year high for Change in Account Payables was $5951.0 in Q3 2022, with the low at -$10259.0 in Q1 2023.
- The 5-year median for Change in Account Payables is $165.0 (2024), against an average of -$246.53.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables tumbled 920.72% in 2023, then soared 157.95% in 2024.
- Greater Cannabis Company's Change in Account Payables stood at $1954.0 in 2022, then jumped by 40.94% to $2754.0 in 2023, then tumbled by 46.95% to $1461.0 in 2024, then slumped by 122.93% to -$335.0 in 2025, then tumbled by 198.51% to -$1000.0 in 2026.
- Business Quant data shows GCAN's Change in Account Payables at -$1000.0 in Q1 2026, -$335.0 in Q4 2025, and $2056.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.86 Bn | 42.90 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.54 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.79 Bn | 1.05 Bn | -53.00 Mn |
| 4 | Takeda Pharmaceutical | 28.57 Bn | 22.77 Bn | 5.10 Bn | -143.74 Mn |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -21.20 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.71 Bn | 11.18 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,000.00 |
| Mar 31, 2026 | -1,000.00 |
| Dec 31, 2025 | -335.00 |
| Dec 31, 2025 | -335.00 |
| Sep 30, 2025 | 2,056.00 |
| Sep 30, 2025 | 2,056.00 |
| Jun 30, 2025 | -1,251.00 |
| Jun 30, 2025 | -1,251.00 |
| Mar 31, 2025 | 165.00 |
| Mar 31, 2025 | 165.00 |
| Dec 31, 2024 | 1,461.00 |
| Dec 31, 2024 | 1,461.00 |
| Sep 30, 2024 | 1,159.00 |
| Sep 30, 2024 | 1,159.00 |
| Jun 30, 2024 | -1,000.00 |
| Jun 30, 2024 | -1,000.00 |
| Mar 31, 2024 | 165.00 |
| Mar 31, 2024 | 165.00 |
| Dec 31, 2023 | 2,754.00 |
| Dec 31, 2023 | 2,754.00 |